Pekrul Isabell, Schachtner Thomas, Zwißler Bernhard, Möhnle Patrick
Klinik für Anaesthesiologie, Abteilung für Transfusionsmedizin, Zelltherapeutika und Hämostaseologie, Universität München (LMU), Marchioninistr. 15, 81377, München, Deutschland.
Anästhesie und Intensivmedizin, Schön Klinik München Harlaching, München, Deutschland.
Anaesthesist. 2021 Jun;70(6):515-521. doi: 10.1007/s00101-021-00928-5. Epub 2021 Feb 23.
The use of tranexamic acid (TXA) is established in the treatment of bleeding, especially of bleeding due to hyperfibrinolysis. In recent years the prophylactic use of TXA in trauma and orthopedic surgery has increased leading to open questions regarding potentially associated risks and a possible classification as off label use. The available literature provides a sound basis for the recommendation that TXA can be used in these indications provided that an individual risk assessment is done in patients with increased risks for thromboembolic complications. Although the prophylactic use of TXA in orthopedic surgery and trauma is not explicitly listed in the product characteristics, it should not be regarded as an off label use.
氨甲环酸（TXA）已被用于治疗出血，尤其是高纤溶引起的出血。近年来，TXA在创伤和骨科手术中的预防性使用有所增加，这引发了关于潜在相关风险以及是否可能被归类为超说明书用药的诸多问题。现有文献为以下建议提供了可靠依据：在对血栓栓塞并发症风险增加的患者进行个体风险评估后，TXA可用于这些适应症。尽管TXA在骨科手术和创伤中的预防性使用未在产品说明书中明确列出，但不应将其视为超说明书用药。
